You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Lantheus Medcl Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for LANTHEUS MEDCL, and what generic alternatives to LANTHEUS MEDCL drugs are available?

LANTHEUS MEDCL has nine approved drugs.

There are nine US patents protecting LANTHEUS MEDCL drugs.

There are sixty-nine patent family members on LANTHEUS MEDCL drugs in seventeen countries and eight supplementary protection certificates in five countries.

Summary for Lantheus Medcl
International Patents:69
US Patents:9
Tradenames:10
Ingredients:8
NDAs:9

Drugs and US Patents for Lantheus Medcl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Lantheus Medcl TECHNELITE technetium tc-99m sodium pertechnetate generator SOLUTION;INTRAVENOUS 017771-002 Feb 12, 2014 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes 11,529,431 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Lantheus Medcl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 8,394,356 ⤷  Try a Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 5,769,080 ⤷  Try a Trial
Lantheus Medcl DEFINITY perflutren INJECTABLE;INTRAVENOUS 021064-001 Jul 31, 2001 9,545,457 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Lantheus Medcl Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0806968 PA2007003,C0806968 Lithuania ⤷  Try a Trial PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
0712293 C300267 Netherlands ⤷  Try a Trial PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
0712293 0790017-8 Sweden ⤷  Try a Trial PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.